Due to these potential therapeutic effects, ALK5 inhibitors have been identified as a target for the development of therapeutic agents not only for patients with MF but also for patients with numerous solid and blood cancers. This evidence concerns the gene TGFBR1 and hematopoietic and lymphoid system neoplasm.